Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11beta-hydroxysteroid-dehydrogenase type 1.
Venier, O., Pascal, C., Braun, A., Namane, C., Mougenot, P., Crespin, O., Pacquet, F., Mougenot, C., Monseau, C., Onofri, B., Dadji-Faihun, R., Leger, C., Ben-Hassine, M., Van-Pham, T., Ragot, J.L., Philippo, C., Gussregen, S., Engel, C., Farjot, G., Noah, L., Maniani, K., Nicolai, E.(2011) Bioorg Med Chem Lett 21: 2244-2251
- PubMed: 21439819 
- DOI: https://doi.org/10.1016/j.bmcl.2011.02.111
- Primary Citation of Related Structures:  
3QQP - PubMed Abstract: 
A High Throughput Screening campaign allowed the identification of a novel class of ureas as 11β-HSD1 inhibitors. Rational chemical optimization provided potent and selective inhibitors of both human and murine 11β-HSD1 with an appropriate ADME profile and ex vivo activity in target tissues.
Organizational Affiliation: 
Sanofi-aventis R&D, 1 Avenue Pierre Brossolette, 91385 Chilly-Mazarin, France. Olivier.Venier@sanofi-aventis.com